Skip to main content


Log in

Dynamic contrast-enhanced CT to assess metabolic response in patients with advanced non-small cell lung cancer and stable disease after chemotherapy or chemoradiotherapy

  • Chest
  • Published:
European Radiology Aims and scope Submit manuscript



To compare tumour enhancement patterns measured using dynamic contrast-enhanced (DCE)-CT with tumour metabolism measured using positron emission tomography (PET)-CT in patients with non-small cell lung cancer (NSCLC) and stable disease after chemotherapy or chemoradiotherapy.


After treatment, 75 NSCLC tumours in 65 patients who had stable disease on DCE-CT according to Response Evaluation Criteria in Solid Tumour (RECIST) were evaluated using PET-CT. On DCE-CT, relative enhancement ratios (RER) of tumour at 30, 60, 90, 120 s and 5 min after injection of contrast material were measured. Metabolic responses of tumours were classified into two groups according to the maximum standardized uptake value (SUVmax) by PET-CT: complete metabolic response (CR) with an SUVmax of less than 2.5, and noncomplete metabolic response (NR) with an SUVmax of at least 2.5.


Using the optimal RER60 cutoff value of 43.7 % to predict NR of tumour gave 95.7 % sensitivity, 64.2 % specificity, and 82.1 % positive and 95.0 % negative predictive values. After adjusting for tumour size, the odds ratio for NR in tumour with an RER60 of at least 43.7 % was 70.85 (95 % CI = 7.95–630.91; P < 0.05).


Even when disease was stable according to RECIST, DCE-CT predicted hypermetabolic status of residual tumour in patients with NSCLC after treatment.

Key Points

Dynamic contrast-enhanced CT (DCE-CT) can provide useful metabolic information about non-small cell lung cancer.

NSCLC lesions, even grossly stable after treatment, show various metabolic states.

DCE-CT enhancement patterns correlate with tumour metabolic status as shown by PET.

DCE-CT helps to assess hypermetabolic NSCLC as stable disease after treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others


  1. Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71–96

    Article  PubMed  Google Scholar 

  2. Alberg AJ, Ford JG, Samet JM (2007) Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132:29S–55S

    Article  PubMed  CAS  Google Scholar 

  3. Laskin JJ, Sandler AB (2005) State of the art in therapy for non-small cell lung cancer. Cancer Invest 23:427–442

    Article  PubMed  Google Scholar 

  4. Cooper S, Spiro SG (2006) Small cell lung cancer: treatment review. Respirology 11:241–248

    Article  PubMed  Google Scholar 

  5. Watanabe H, Yamamoto S, Kunitoh H et al (2003) Tumor response to chemotherapy: the validity and reproducibility of RECIST guidelines in NSCLC patients. Cancer Sci 94:1015–1020

    Article  PubMed  CAS  Google Scholar 

  6. Suzuki C, Jacobsson H, Hatschek T et al (2008) Radiologic measurements of tumor response to treatment: practical approaches and limitations. Radiographics 28:329–344

    Article  PubMed  Google Scholar 

  7. Erasmus JJ, Gladish GW, Broemeling L et al (2003) Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol 21:2574–2582

    Article  PubMed  Google Scholar 

  8. Mazumdar M, Smith A, Schwartz LH (2004) A statistical simulation study finds discordance between WHO criteria and RECIST guideline. J Clin Epidemiol 57:358–365

    Article  PubMed  Google Scholar 

  9. Tran LN, Brown MS, Goldin JG et al (2004) Comparison of treatment response classifications between unidimensional, bidimensional, and volumetric measurements of metastatic lung lesions on chest computed tomography. Acad Radiol 11:1355–1360

    Article  PubMed  Google Scholar 

  10. Young H, Baum R, Cremerius U et al (1999) Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35:1773–1782

    Article  PubMed  CAS  Google Scholar 

  11. Juweid ME, Cheson BD (2006) Positron-emission tomography and assessment of cancer therapy. N Engl J Med 354:496–507

    Article  PubMed  CAS  Google Scholar 

  12. Huang W, Zhou T, Ma L et al (2011) Standard uptake value and metabolic tumor volume of (1)F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer. Eur J Nucl Med Mol Imaging 38:1628–1635

    Article  PubMed  CAS  Google Scholar 

  13. Cuenod CA, Fournier L, Balvay D, Guinebretiere JM (2006) Tumor angiogenesis: pathophysiology and implications for contrast-enhanced MRI and CT assessment. Abdom Imaging 31:188–193

    Article  PubMed  CAS  Google Scholar 

  14. Schaefer JF, Vollmar J, Schick F et al (2004) Solitary pulmonary nodules: dynamic contrast-enhanced MR imaging: perfusion differences in malignant and benign lesions. Radiology 232:544–553

    Article  PubMed  Google Scholar 

  15. Yi CA, Lee KS, Kim EA et al (2004) Solitary pulmonary nodules: dynamic enhanced multi-detector row CT study and comparison with vascular endothelial growth factor and microvessel density. Radiology 233:191–199

    Article  PubMed  Google Scholar 

  16. Jeong YJ, Lee KS, Jeong SY et al (2005) Solitary pulmonary nodule: characterization with combined wash-in and washout features at dynamic multi-detector row CT. Radiology 237:675–683

    Article  PubMed  Google Scholar 

  17. Swensen SJ, Viggiano RW, Midthun DE et al (2000) Lung nodule enhancement at CT: multicenter study. Radiology 214:73–80

    PubMed  CAS  Google Scholar 

  18. Wang J, Wu N, Cham MD, Song Y (2009) Tumor response in patients with advanced non-small cell lung cancer: perfusion CT evaluation of chemotherapy and radiation therapy. AJR Am J Roentgenol 193:1090–1096

    Article  PubMed  Google Scholar 

  19. Lind JS, Meijerink MR, Dingemans AM et al (2010) Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment? Eur Radiol 20:2890–2898

    Article  PubMed  Google Scholar 

  20. Kiessling F, Boese J, Corvinus C et al (2004) Perfusion CT in patients with advanced bronchial carcinomas: a novel chance for characterization and treatment monitoring? Eur Radiol 14:1226–1233

    PubMed  CAS  Google Scholar 

  21. Pezzella F, Pastorino U, Tagliabue E et al (1997) Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol 151:1417–1423

    PubMed  CAS  Google Scholar 

  22. Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma. N Engl J Med 324:1–8

    Article  PubMed  CAS  Google Scholar 

  23. Valentin J (2000) Avoidance of radiation injuries from medical interventional procedures. Ann ICRP 30:7–67

    PubMed  CAS  Google Scholar 

  24. Decoster L, Schallier D, Everaert H et al (2008) Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC). Lung Cancer 62:55–61

    Article  PubMed  CAS  Google Scholar 

  25. Bellomi M, Petralia G, Sonzogni A, Zampino MG, Rocca A (2007) CT perfusion for the monitoring of neoadjuvant chemotherapy and radiation therapy in rectal carcinoma: initial experience. Radiology 244:486–493

    Article  PubMed  Google Scholar 

  26. Yamashita K, Matsunobe S, Tsuda T et al (1995) Solitary pulmonary nodule: preliminary study of evaluation with incremental dynamic CT. Radiology 194:399–405

    PubMed  CAS  Google Scholar 

  27. Dean PB, Niemi P, Kivisaari L, Kormano M (1988) Comparative pharmacokinetics of gadolinium DTPA and gadolinium chloride. Invest Radiol 23:S258–S260

    Article  PubMed  CAS  Google Scholar 

  28. Patz EF Jr, Connolly J, Herndon J (2000) Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer. AJR Am J Roentgenol 174:769–774

    Article  PubMed  Google Scholar 

Download references


This work was supported by the LG Life Sciences Radiology Research Fund in 2010 (3-2010-0084).

Author information

Authors and Affiliations


Corresponding author

Correspondence to Tae Hoon Kim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hwang, S.H., Yoo, M.R., Park, C.H. et al. Dynamic contrast-enhanced CT to assess metabolic response in patients with advanced non-small cell lung cancer and stable disease after chemotherapy or chemoradiotherapy. Eur Radiol 23, 1573–1581 (2013).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: